WO2004094655A3 - Modulation of telomere-initiated cell signaling - Google Patents

Modulation of telomere-initiated cell signaling Download PDF

Info

Publication number
WO2004094655A3
WO2004094655A3 PCT/US2004/000819 US2004000819W WO2004094655A3 WO 2004094655 A3 WO2004094655 A3 WO 2004094655A3 US 2004000819 W US2004000819 W US 2004000819W WO 2004094655 A3 WO2004094655 A3 WO 2004094655A3
Authority
WO
WIPO (PCT)
Prior art keywords
telomere
modulation
cell signaling
initiated cell
initiated
Prior art date
Application number
PCT/US2004/000819
Other languages
French (fr)
Other versions
WO2004094655A2 (en
Inventor
Barbara A Gilchrest
Mark Eller
Original Assignee
Univ Boston
Barbara A Gilchrest
Mark Eller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/011393 external-priority patent/WO2003087411A1/en
Application filed by Univ Boston, Barbara A Gilchrest, Mark Eller filed Critical Univ Boston
Priority to EP04702134A priority Critical patent/EP1620562A4/en
Priority to JP2006508599A priority patent/JP2007525162A/en
Priority to US10/553,001 priority patent/US20060269924A1/en
Priority to AU2004233188A priority patent/AU2004233188A1/en
Priority to CA002519897A priority patent/CA2519897A1/en
Publication of WO2004094655A2 publication Critical patent/WO2004094655A2/en
Publication of WO2004094655A3 publication Critical patent/WO2004094655A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The use of modulators of Mre 11, tankyrase, the DNA damage pathway and MRN complex formation of the protection of mammals from failure of growth arrest, apoptosis or proliferative senescence.
PCT/US2004/000819 2003-04-11 2004-01-14 Modulation of telomere-initiated cell signaling WO2004094655A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04702134A EP1620562A4 (en) 2003-04-11 2004-01-14 Modulation of telomere-initiated cell signaling
JP2006508599A JP2007525162A (en) 2003-04-11 2004-01-14 Regulation of cell signaling initiated by telomeres
US10/553,001 US20060269924A1 (en) 2003-04-11 2004-01-14 Modulation of telomere-initiated cell signaling
AU2004233188A AU2004233188A1 (en) 2003-04-11 2004-01-14 Modulation of telomere-initiated cell signaling
CA002519897A CA2519897A1 (en) 2003-04-11 2004-01-14 Modulation of telomere-initiated cell signaling

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US03/11393 2003-04-11
PCT/US2003/011393 WO2003087411A1 (en) 2002-04-12 2003-04-11 Method to inhibit cell growth using oligonucleotides

Publications (2)

Publication Number Publication Date
WO2004094655A2 WO2004094655A2 (en) 2004-11-04
WO2004094655A3 true WO2004094655A3 (en) 2006-09-14

Family

ID=33308983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000819 WO2004094655A2 (en) 2003-04-11 2004-01-14 Modulation of telomere-initiated cell signaling

Country Status (5)

Country Link
EP (1) EP1620562A4 (en)
JP (3) JP2007525162A (en)
AU (1) AU2004233188A1 (en)
CA (1) CA2519897A1 (en)
WO (1) WO2004094655A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06013263A (en) 2004-05-19 2007-08-14 Univ Boston Modulation of wrn-mediated telomere-initiated cell signaling.
KR100835747B1 (en) 2006-08-25 2008-06-09 고려대학교 산학협력단 Mre11 protein relating to aging and methods of controlling aging by using it

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958680A (en) * 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3117999A (en) * 1998-03-27 1999-10-18 Icos Corporation Human rad1 cell cycle checkpoint
JP2001231567A (en) 2000-02-18 2001-08-28 Inst Of Physical & Chemical Res Method for regulating telomere length
US7358040B2 (en) * 2001-08-01 2008-04-15 Rigel Pharmaceuticals, Incorporated MRE 11: modulation of cellular proliferation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958680A (en) * 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANSELMET ET AL.: "Non-antisense cellular responses to oligonucleotides", FEBS LETTERS, vol. 510, no. 3, 16 January 2002 (2002-01-16), pages 175 - 180, XP004332636 *
GLUKHOV ET AL.: "Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 248, no. 2, 20 July 1998 (1998-07-20), pages 368 - 371, XP000961269 *
See also references of EP1620562A4 *
ZHIHUI ET AL.: "Inhibitory effect of a liposome-mediated antisense oligodeoxynucleotide on telomerase activity in a human gastric cancer cell line", CHINESE JOURNAL OF DIGESTIVE DISEASES, vol. 2, 2001, pages 65 - 68, XP003012222 *

Also Published As

Publication number Publication date
JP2007525162A (en) 2007-09-06
AU2004233188A1 (en) 2004-11-04
JP2010279367A (en) 2010-12-16
CA2519897A1 (en) 2004-11-04
EP1620562A2 (en) 2006-02-01
JP2011103889A (en) 2011-06-02
EP1620562A4 (en) 2007-06-27
WO2004094655A2 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
WO2006007411A3 (en) Methods and compositions for modulating bax-mediated apoptosis
ZA200302808B (en) Systems and methods for providing colour management.
WO2005048047A3 (en) Systems and methods for network coordination with limited explicit message exchange
PL378754A1 (en) 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators
WO2009035902A3 (en) Malware prevention system monitoring kernel events
WO2006036994A3 (en) Modulators of crth2, cox-2 and faah
MXPA05008701A (en) Monitoring and automatic equipment control systems.
AU2003220394A1 (en) Syringe with integral safety system
WO2001074815A3 (en) Phenyl-substituted imidazopyridines
AU2003273717A1 (en) Application level security
WO2007112367A3 (en) Potassium channel modulators and platelet procoagulant activity
AU2003235952A1 (en) Hanger for rope or the like
WO2006050333A3 (en) Methods and compositions for modulating apoptosis
AU2003226785A1 (en) Line guidance unit for the active guidance of lines, cables or similar
WO2005056042A3 (en) Methods of protecting against radiation using flagellin
AU2003218099A1 (en) Modulation of the immune response through the manipulation of arginine levels
DE60224785D1 (en) TURNING ANGLE DETECTOR AND EQUIPMENT WITH THE DETECTOR
AU2003209385A1 (en) Aircraft with security alarm system
AU2002242175A1 (en) Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a
WO2004094655A3 (en) Modulation of telomere-initiated cell signaling
NO20001783L (en) Antifouling agents containing thiacloprid
AU2003274787A1 (en) Cap of can for drinking and can for drinking having the same
AU2002235883A1 (en) 2-heteroaryl-3,4-dihydro-2H-pyrrole derivatives and the use thereof as pesticides
DE29822443U1 (en) Fall protection for lifting tables, lifting platforms and the like.
AU2003242899A1 (en) Primary pan-vehicular safety systems

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2519897

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004233188

Country of ref document: AU

Ref document number: 2006508599

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004233188

Country of ref document: AU

Date of ref document: 20040114

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004233188

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004702134

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004702134

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006269924

Country of ref document: US

Ref document number: 10553001

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10553001

Country of ref document: US